Invesaro

Stocks Comparison

Intellia Therapeutics vs Trinity Biotech: revenue, profit, margins and growth compared

Intellia Therapeutics brought in $67.7M of revenue in fiscal 2025, Trinity Biotech $61.6M in fiscal 2024. Revenue changed by +16.9% at Intellia Therapeutics and +8.3% at Trinity Biotech on the year before, so Intellia Therapeutics grew faster. Intellia Therapeutics kept -609.9% of its revenue as net profit, Trinity Biotech -51.6%. Free cash flow was -$395.9M at Intellia Therapeutics and -$4.6M at Trinity Biotech.

Side by side, latest fiscal year

NTLATRIB
Fiscal year endedFY2025 (December 31, 2025)FY2024 (December 31, 2024)
Revenue$67.7M$61.6M
Revenue growth+16.9%+8.3%
Net income-$412.7M-$31.8M
Net margin-609.9%-51.6%
Free cash flow-$395.9M-$4.6M
Free cash flow margin-585.0%-7.5%
Earnings per share (diluted)-$3.81n/a
Cash$155.5M$5.2M
Debt$0n/a
Price to earningsn/an/a
Market value$1.6B$4.7M
Dividend yieldn/an/a
Rank by revenue in sector#369 of 751 · Health care#381 of 751 · Health care

Over the years

Revenue
NTLA FY2018: $30.4MNTLA FY2019: $43.1MNTLA FY2020: $58MNTLA FY2021: $33.1MNTLA FY2022: $52.1MNTLA FY2023: $36.3MNTLA FY2024: $57.9MNTLA FY2025: $67.7MTRIB FY2017: $99.1MTRIB FY2018: $97MTRIB FY2019: $90.4MTRIB FY2020: $102MTRIB FY2021: $81.1MTRIB FY2022: $62.5MTRIB FY2023: $56.8MTRIB FY2024: $61.6MFY17FY18FY19FY20FY21FY22FY23FY24FY25
NTLA $67.7MTRIB $61.6M
Net income
NTLA FY2018: -$85.3MNTLA FY2019: -$474.2MNTLA FY2020: -$134.2MNTLA FY2021: -$267.9MNTLA FY2022: -$474.2MNTLA FY2023: -$481.2MNTLA FY2024: -$519MNTLA FY2025: -$412.7MTRIB FY2017: -$40.3MTRIB FY2018: -$22.1MTRIB FY2019: -$28.9MTRIB FY2020: -$6.4MTRIB FY2021: $875KTRIB FY2022: -$41MTRIB FY2023: -$24MTRIB FY2024: -$31.8MFY17FY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$412.7MTRIB -$31.8M
Net margin
NTLA FY2018: -280.4%NTLA FY2019: -1,100.1%NTLA FY2020: -231.5%NTLA FY2021: -810.5%NTLA FY2022: -909.8%NTLA FY2023: -1,326.5%NTLA FY2024: -896.8%NTLA FY2025: -609.9%TRIB FY2017: -40.6%TRIB FY2018: -22.8%TRIB FY2019: -32.0%TRIB FY2020: -6.3%TRIB FY2021: 1.1%TRIB FY2022: -65.6%TRIB FY2023: -42.3%TRIB FY2024: -51.6%FY17FY18FY19FY20FY21FY22FY23FY24FY25
NTLA -609.9%TRIB -51.6%
Revenue growth
NTLA FY2019: +41.6%NTLA FY2020: +34.5%NTLA FY2021: -43.0%NTLA FY2022: +57.7%NTLA FY2023: -30.4%NTLA FY2024: +59.6%NTLA FY2025: +16.9%TRIB FY2018: -2.1%TRIB FY2019: -6.8%TRIB FY2020: +12.8%TRIB FY2021: -20.4%TRIB FY2022: -23.0%TRIB FY2023: -9.1%TRIB FY2024: +8.3%FY18FY19FY20FY21FY22FY23FY24FY25
NTLA +16.9%TRIB +8.3%
Free cash flow
NTLA FY2018: -$67.6MNTLA FY2019: -$110MNTLA FY2020: -$53.5MNTLA FY2021: -$237.8MNTLA FY2022: -$346.8MNTLA FY2023: -$408.1MNTLA FY2024: -$354.7MNTLA FY2025: -$395.9MTRIB FY2017: $4.4MTRIB FY2018: -$299KTRIB FY2019: $3.3MTRIB FY2020: $20.6MTRIB FY2021: $11.4MTRIB FY2022: -$2MTRIB FY2023: -$12.4MTRIB FY2024: -$4.6MFY17FY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$395.9MTRIB -$4.6M

Fiscal years as each company reports them; the two may end in different months.

Questions about Intellia Therapeutics and Trinity Biotech

Which is bigger by revenue, Intellia Therapeutics or Trinity Biotech?

Intellia Therapeutics is bigger by revenue: $67.7M in fiscal 2025, against $61.6M for Trinity Biotech in fiscal 2024.

Which keeps more of its revenue as profit, Intellia Therapeutics or Trinity Biotech?

Intellia Therapeutics had a net margin of -609.9% in fiscal 2025; Trinity Biotech had -51.6% in fiscal 2024.

Which grew revenue faster, Intellia Therapeutics or Trinity Biotech?

In their latest fiscal years revenue changed by +16.9% at Intellia Therapeutics and +8.3% at Trinity Biotech.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies